IL-20 Bone Diseases Involvement and Therapeutic Target Potential

Overview

Journal J Biomed Sci

Publisher Biomed Central

Specialty Biology

Date 2018 Apr 26

PMID 29690863

Citations 6

Authors

Hsiao-Hsuan Wang

Yu-Hsiang Hsu

Ming-Shi Chang

Affiliations

Soon will be listed here.

Abstract

Background: Millions of people around the world suffer from bone disorders, likes osteoporosis, rheumatoid arthritis (RA), and cancer-induced osteolysis. In general, the bone remodeling balance is determined by osteoclasts and osteoblasts, respectively responsible for bone resorption and bone formation. Excessive inflammation disturbs the activities of these two kinds of cells, typically resulting in the bone loss.

Main Body: IL-20 is emerging as a potent angiogenic, chemotactic, and proinflammatory cytokine related to several chronic inflammatory disorders likes psoriasis, atherosclerosis, cancer, liver fibrosis, and RA. IL-20 has an important role in the regulation of osteoclastogenesis and osteoblastogenesis and is upregulated in several bone-related diseases. The anti-IL-20 monoclonal antibody treatment has a therapeutic potential in several experimental disease models including ovariectomy-induced osteoporosis, cancer-induced osteolysis, and bone fracture.

Conclusion: This review article provides an overview describing the IL-20's biological functions in the common bone disorders and thus providing a novel therapeutic strategy in the future.

Citing Articles

The role of interleukin-20 on inflammatory stress and periodontal tissue destruction in patients with metabolic syndrome and periodontitis.

Senkal R, Yemenoglu H, Kose O, Karakas S, Yilmaz A, Akyildiz K BMC Oral Health. 2024; 24(1):1423.

PMID: 39578819 PMC: 11583481. DOI: 10.1186/s12903-024-05224-3.

The causal relationship between autoimmune diseases and rhinosinusitis, and the mediating role of inflammatory proteins: a Mendelian randomization study.

Liang Y, Yin S, Chen X, Li C, Chen Q Exp Biol Med (Maywood). 2024; 249:10196.

PMID: 39104791 PMC: 11299433. DOI: 10.3389/ebm.2024.10196.

The role of interleukin-20 in liver disease: Functions, mechanisms and clinical applications.

Wang K, Zhan H, Hu Y, Yuan Z, Yang J, Yang D Heliyon. 2024; 10(9):e29853.

PMID: 38699038 PMC: 11064155. DOI: 10.1016/j.heliyon.2024.e29853.

From Cells to Environment: Exploring the Interplay between Factors Shaping Bone Health and Disease.

Singh S, Sarma D, Verma V, Nagpal R, Kumar M Medicina (Kaunas). 2023; 59(9).

PMID: 37763665 PMC: 10532995. DOI: 10.3390/medicina59091546.

Exploring the JAK/STAT Signaling Pathway in Hepatocellular Carcinoma: Unraveling Signaling Complexity and Therapeutic Implications.

Park H, Lee S, Lee J, Moon H, Ro S Int J Mol Sci. 2023; 24(18).

PMID: 37762066 PMC: 10531214. DOI: 10.3390/ijms241813764.

References

BLUMBERG H, Conklin D, Xu W, Grossmann A, Brender T, Carollo S . Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell. 2001; 104(1):9-19. DOI: 10.1016/s0092-8674(01)00187-8. View

Otkjaer K, Kragballe K, Johansen C, Funding A, Just H, Jensen U . IL-20 gene expression is induced by IL-1beta through mitogen-activated protein kinase and NF-kappaB-dependent mechanisms. J Invest Dermatol. 2007; 127(6):1326-36. DOI: 10.1038/sj.jid.5700713. View

Braschi E, Shojania K, Allan G . Anti-CCP: a truly helpful rheumatoid arthritis test?. Can Fam Physician. 2016; 62(3):234. PMC: 4984588. View

Liu X, Zhou H, Huang X, Cui J, Long T, Xu Y . A Broad Blockade of Signaling from the IL-20 Family of Cytokines Potently Attenuates Collagen-Induced Arthritis. J Immunol. 2016; 197(8):3029-3037. DOI: 10.4049/jimmunol.1600399. View

Gaffen S . The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep. 2009; 11(5):365-70. PMC: 2811488. DOI: 10.1007/s11926-009-0052-y. View

Hsu Y, Wei C, Shieh D, Chan C, Chang M . Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses tumor growth. Mol Cancer Res. 2012; 10(11):1430-9. DOI: 10.1158/1541-7786.MCR-12-0276. View

Huber L, Distler O, Tarner I, Gay R, Gay S, Pap T . Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford). 2006; 45(6):669-75. DOI: 10.1093/rheumatology/kel065. View

Feldmann M . Many cytokines are very useful therapeutic targets in disease. J Clin Invest. 2008; 118(11):3533-6. PMC: 2575703. DOI: 10.1172/JCI37346. View

Leng R, Pan H, Tao J, Ye D . IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases. Expert Opin Ther Targets. 2010; 15(2):119-26. DOI: 10.1517/14728222.2011.534461. View

10.

Feng X, McDonald J . Disorders of bone remodeling. Annu Rev Pathol. 2010; 6:121-45. PMC: 3571087. DOI: 10.1146/annurev-pathol-011110-130203. View

11.

Patel L, Camacho D, Shiozawa Y, Pienta K, Taichman R . Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncol. 2011; 7(11):1285-97. PMC: 3258525. DOI: 10.2217/fon.11.112. View

12.

Hsu Y, Hsieh P, Chang M . Interleukin-19 blockade attenuates collagen-induced arthritis in rats. Rheumatology (Oxford). 2011; 51(3):434-42. DOI: 10.1093/rheumatology/ker127. View

13.

Hsu Y, Wu C, Hsing C, Lai W, Wu L, Chang M . Anti-IL-20 Monoclonal Antibody Suppresses Prostate Cancer Growth and Bone Osteolysis in Murine Models. PLoS One. 2015; 10(10):e0139871. PMC: 4594924. DOI: 10.1371/journal.pone.0139871. View

14.

Kragstrup T, Andersen M, Schiottz-Christensen B, Jurik A, Hvid M, Deleuran B . Increased interleukin (IL)-20 and IL-24 target osteoblasts and synovial monocytes in spondyloarthritis. Clin Exp Immunol. 2017; 189(3):342-351. PMC: 5543495. DOI: 10.1111/cei.12973. View

15.

Tsai J, Yang J . Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013; 27(20):2192-206. PMC: 3814640. DOI: 10.1101/gad.225334.113. View

16.

Valentina M, Jan F, Peder N, Bo Z, Hongjie D, Pernille K . Cytokine detection and simultaneous assessment of rheumatoid factor interference in human serum and synovial fluid using high-sensitivity protein arrays on plasmonic gold chips. BMC Biotechnol. 2015; 15:73. PMC: 4535377. DOI: 10.1186/s12896-015-0186-0. View

17.

Wada T, Nakashima T, Hiroshi N, Penninger J . RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2005; 12(1):17-25. DOI: 10.1016/j.molmed.2005.11.007. View

18.

Redig A, McAllister S . Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013; 274(2):113-26. PMC: 3711134. DOI: 10.1111/joim.12084. View

19.

Hsu Y, Li H, Hsieh M, Liu M, Huang K, Chin L . Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum. 2006; 54(9):2722-33. DOI: 10.1002/art.22039. View

20.

Le Gall C, Bonnelye E, Clezardin P . Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care. 2008; 2(3):218-22. DOI: 10.1097/SPC.0b013e32830baea9. View